Spearheading Fast Progression of TTX-381 through the Value Chain to Tackle Rapid Onset of Rare Diseases
Time: 10:00 am
day: Conference Day Two
Details:
- Discussing the necessity of accelerating Tern Therapeutics TTX-381 development to provide patients with CLN2 Disease an alternative therapy
- Highlighting the steps taken to maximize speed of development and efficacy of therapy to ensure regulatory approval and quick accessibility
- Evaluating the goals for TTX-381 for the next year to encourage rapid progression of therapies for other rare ophthalmic diseases
